Delving into the Latest Updates on TISSUE REGENERATION(Froceth) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

SVF-CURE

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

EnthesopathyOsteoarthritisOsteochondritis+ [1]

Inactive Indication-

Originator Organization

Froceth

Active Organization

Froceth

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

BACKGROUND AND OBJECTIVESBotulinum toxin type A (BTA) is often used for wrinkles and muscle convulsive diseases due to its blocking of the transmission of nerve impulses. Stromal vascular fraction gel (SVF-gel) prepared from adipose tissue has novel effects on skin depression and poor texture. Both BTA and SVF-gel are proved to possess anti-scar potential. This study aimed to assess and compare their therapeutic effects on hypertrophic scars.MATERIALS AND METHODSThe rabbit ear scar model was established and treated with BTA and SVF-gel, alone or in combination. Gross evaluation using Manchester Scar Scale (MSS) was conducted immediately, 4 and 8 weeks after initial treatment. After tissue sample harvest, histological and Western blot analyses were performed.RESULTSAll the treatments alleviated scar hyperplasia in different degrees by inhibiting fibroblast activation (Ki-67, α-SMA), tissue inflammation (CD45, IL-1β) and the transforming growth factor-β1 (TGF-β1)/Smad3 pathway. Despite an excellent anti-inflammatory effect, improvement of scar appearance and pathological characteristics in SVF-gel-contained groups was not as good as that in BTA-only group, which might be related to the retention of M2-type macrophages (CD163 +) and partial maintenance of TGF-β1 expression.CONCLUSIONOur data suggest that BTA has better anti-scar efficacy than SVF-gel, and the combination of these two treatments shows no obvious combinatorial effect.

100 Deals associated with TISSUE REGENERATION(Froceth)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Enthesopathy	Preclinical	LT	Froceth	26 Aug 2024
Osteoarthritis	Preclinical	LT	Froceth	26 Aug 2024
Osteochondritis	Preclinical	LT	Froceth	26 Aug 2024
Osteochondrosis	Preclinical	LT	Froceth	26 Aug 2024